Citeline’s experts analyze real patient enrollment speeds, map therapeutic strengths, and deliver actionable strategies across every stage of development. Discover how to accelerate clinical trial timeline and maximize biopharma opportunities in China.
Development timelines and costs are rising across the US and Europe. Regulations are tight, competition is fierce, and patient availability is a challenge as trial complexity rises. But China offers biopharma companies the opportunity to shave years off drug development, and with it, bring faster access to new treatments for patients.
China has already established itself as a serious source of innovation, especially in oncology and next-generation biologics. Industry anecdotes also suggest that it is 40% faster and 50% cheaper to develop a novel drug in China than in the West. But as more companies turn to China, that advantage is starting to narrow. So how do the benefits stack up today, and where does the West still hold the edge?
Using proprietary insights, Citeline's experts go beyond the headline figure. They'll quantify how much faster China can be on patient enrolment, from trial disclosure to first patient enrolled, and map its strengths across therapy areas, modalities and technologies. Above all, they'll set out how biopharmas can take advantage of the opportunity in China across each stage of development.
We’ll cover:
